Original Articles: Mechanisms of AllergyLate asthmatic reactions provoked by intradermal injection of T-cell peptide epitopes are not associated with bronchial mucosal infiltration of eosinophils or TH2-type cells or with elevated concentrations of histamine or eicosanoids in bronchoalveolar fluid☆,☆☆
Section snippets
Study design
All subjects were documented cat-allergic asthmatic individuals, as defined previously.1 Thirty-four people entered the study. At each initial assessment, the study was explained in detail and the patient completed an asthma and allergy questionnaire that recorded sensitivity to allergens, asthma symptoms, and general health and medication information. Each of the 34 patients was given a physical examination, and allergic status was assessed by skin prick tests to a panel of common
Cutaneous and asthmatic reactions to intradermal Fel d 1 chain 1 peptides
Six of the 8 patients studied had no visible local cutaneous reaction to the FC1P. Each of 2 subjects developed a wheal that was slightly larger than that observed with diluent alone at 15 minutes (though smaller than that observed with whole allergen). One subject had a visible late cutaneous reaction to intradermal injection of FC1P at 6 hours. None of the 26 FC1P nonresponders had late cutaneous reactions to the peptides. All 34 subjects developed immediate and late-phase cutaneous reactions
Discussion
We recently described IgE-independent isolated LARs elicited by intradermal adminstration of allergen-derived T-cell peptide epitopes. The evidence that linear, allergen-derived, peptide-induced LARs are T cell–dependent includes the following. First, as described previously,1 the FC1P peptides induced T-cell proliferation but not histamine release from peripheral blood basophils. Second, responsiveness of subjects with asthma, in terms of the development of LAR, appears to be MHC class
References (26)
- et al.
Basophils, eosinophils and mast cells in atopic and non-atopic asthma and in late-phase allergic reactions in the lung and skin
J Allergy Clin Immunol
(2000) - et al.
Activation of CD4+ T cells, increased TH2-type cytokine mRNA expression, and eosinophil recruitment in bronchoalveolar lavage after allergen inhalation challenge in atopic asthmatics
J Allergy Clin Immunol
(1993) - et al.
Eosinophils: biology and role in disease
Adv Immunol
(1995) - et al.
Comparative studies of functional and binding assays for IgG anti-Fc~Rkt subunit in chronic urticaria
J Allergy Clin Immunol
(1998) - et al.
Peptide modulation of allergen-specific immune responses
Curr Opin Immunol
(1995) - et al.
Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response
Lancet
(2000) - et al.
IgE-independent MHC-restricted T cell peptide epitope-induced late asthmatic reactions
J Exp Med
(1999) - et al.
Predominant TH2-1ike bronchoalveolar T-lymphocyte population in atopic asthma
N Engl J Med
(1992) - et al.
Identification of activated T lymphocytes and eosinophils in bronchial biopsies in stable atopic asthma
Am Rev Respir Dis
(1990) - et al.
Expression of IL-4 and IL-5 mRNA and protein product by CD4+ and CD8+ T cells, eosinophils, and mast cells in bronchial biopsies obtained from atopic and non atopic (intrinsic) asthmatics
J Immunol
(1997)
Local allergen challenge and bronchoalveolar lavage of allergic asthmatic lungs. Description of the model and local airway inflammation
Am Rev Respir Dis
Increases in activated T lymphocytes, eosinophils, and cytokine mRNA expression for interleukin-5 and granulocyte/macrophage colony-stimulating factor in bronchial biopsies after allergen inhalation challenge in atopic asthmatics
Am J Respir Cell Mol Biol
Allergen-induced increase in non-allergic bronchial reactivity
Clin Allergy
Cited by (60)
Use of recombinant allergens in allergenic immunotherapy
2018, Revue Francaise d'AllergologieEfficacy of 2 months of allergen-specific immunotherapy with Bet v 1–derived contiguous overlapping peptides in patients with allergic rhinoconjunctivitis: Results of a phase IIb study
2016, Journal of Allergy and Clinical ImmunologyCitation Excerpt :Episodes of pulmonary symptoms, such as cough, shortness of breath, or dyspnea, were more frequent in the 100-μg group (55% of the patients) and in the 50-μg group (35%) than in the placebo group (13%), indicating a probable relationship between Bet v 1 COPs and late respiratory systemic reactions. The mechanisms of these late allergic reactions are not fully understood, but most probably are dependent on T-cell activation rather than IgE binding or mast cell or eosinophil activation.28,29 Such respiratory AEs also occurred in AIT trials based on major T-cell epitope peptides, which are unable to bind IgE.27
Prostaglandin D2 inhibits collagen secretion from lung fibroblasts by activating the DP receptor
2013, Journal of Pharmacological SciencesFuture forms of immunotherapy
2011, Journal of Allergy and Clinical ImmunologyCitation Excerpt :It is postulated that these smaller peptides can directly initiate a T cell–dependent late asthmatic reaction without first invoking an early response dependent on IgE or mast cells.51 In 8 patients with late asthmatic reactions, the only changes noted 6 hours after administration of Fel d 1 peptides were increases in CD8+ cell numbers in the skin and a decrease in IL-5 levels in bronchoalveolar lavage fluids but no changes in bronchial biopsy specimens.52 In those patients with late asthmatic responses, reinjection of cat peptide resulted in a marked reduction or complete inhibition of late asthmatic responses that took up to 40 weeks to return.
Therapeutic potential of peptides from Ole e 1 in olive-pollen allergy
2019, Scientific Reports
- ☆
Funded by the National Asthma Campaign (UK), and by GM 15431 from the National Institutes of Health.
- ☆☆
Reprint requests: A.B. Kay, Professor and Head, Department of Allergy and Clinical Immunology, National Heart and Lung Institute, Imperial College School of Medicine, Dovehouse Street, London, SW3 6LY, United Kingdom.